Cancer Vaccines

Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Melanoma Drug Market

Published in Vaccine Weekly, October 1st, 2008

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the malignant melanoma drug market, driven by the launch of emerging agents, will experience robust annual 12 percent growth through 2012 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Thereafter, the market will grow by six percent annually through 2017.

The new Pharmacor report entitled Malignant Melanoma finds that the launch of Bristol-Myers Squibb/Medarex's ipilimumab, first in the metastatic setting and later in the adjuvant setting, will significantly increase the size of the malignant melanoma drug...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2008-10-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry